Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617
Authors
Keywords
Bi-213, Targeting alpha therapy, PSMA, Prostate cancer
Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 45, Issue 1, Pages 31-37
Publisher
Springer Nature
Online
2017-09-11
DOI
10.1007/s00259-017-3817-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
- (2017) Mike Sathekge et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
- (2017) Clemens Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
- (2016) Kambiz Rahbar et al. JOURNAL OF NUCLEAR MEDICINE
- PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- 225Ac-PSMA-617 for PSMA-Targeted -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT
- (2015) Steven P. Rowe et al. ANNALS OF NUCLEAR MEDICINE
- PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer
- (2015) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions
- (2015) A. Afshar-Oromieh et al. JOURNAL OF NUCLEAR MEDICINE
- Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer
- (2015) M. Bene ova et al. JOURNAL OF NUCLEAR MEDICINE
- 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
- (2014) C. Kratochwil et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Half-lives of 221Fr, 217At, 213Bi, 213Po and 209Pb from the 225Ac decay series
- (2013) G. Suliman et al. APPLIED RADIATION AND ISOTOPES
- Radiometabolic Treatment of Bone-Metastasizing Cancer: From 186Rhenium to 223Radium
- (2013) Giuseppe Rubini et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Sequential Cytarabine and -Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia
- (2010) T. L. Rosenblat et al. CLINICAL CANCER RESEARCH
- MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of -Particle Emitters for Targeted Radionuclide Therapy
- (2010) G. Sgouros et al. JOURNAL OF NUCLEAR MEDICINE
- Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer
- (2009) S. M. Hillier et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now